SORL1 and Alzheimer disease: Importantly, blocking PKCι/λ with auranofin disrupts the SORLA-βARR2 interaction, elevates SORLA levels, decreases amyloidogenic processing of APP, and improves cognition in the AppNL−G−F/NL−G−F AD mouse model.